LAUSR

To the Editor—Recent approval of a disease-modifying therapy for Alzheimer’s disease (AD) raises public hopes that other therapeutics may be on the horizon to treat this devastating condition affecting nearly 6 million Americans, including over 180,000 North Carolinians [1]. We are encouraged because at long last we have a drug that can alter the underlying pathology of the illness; however, there are many unanswered questions, particularly when considering whether these treatments will have a meaningful impact on groups underrepresented in clinical trials.